Daniel Chen

Daniel Chen is an immunotherapy scientist and physician whose research has advanced understanding of TGF-beta as a critical driver of the immune excluded tumor phenotype and a therapeutic target to enhance checkpoint inhibitor efficacy. His work contributed to the development and clinical evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting both TGF-beta and PD-L1 simultaneously. He has contributed to understanding how TGF-beta enables immune exclusion through fibroblast activation, epithelial-mesenchymal transition, and direct T-cell suppression. His translational immunotherapy research has shaped combination strategies for cold tumor conversion.